Please login to the form below

Not currently logged in
Email:
Password:

Study suggests SSRI risk for older people

Cohort study suggests new generation antidepressants, SSRIs, may carry greater risks than alternatives for older people

A study has suggested that the new generation of antidepressants, selective serotonin reuptake inhibitors (SSRIs), may have an increased risk for older people.

The study, published in the British Medical Journal (BMJ). indicated that SSRIs are associated with increased levels of several severe adverse outcomes in older people compared to alternative antidepressants such as tricyclics (TCAs).

The cohort investigation, conducted by the University of Nottingham and East Anglia, researched the association between antidepressant treatment and potential life threatening outcomes in patients aged 65 and over.

Overall it was found that SSRIs were associated with an increased risk of all cause mortality, stroke, falls, fracture, epilepsy or seizures and hyponatraemia.

Individual drugs such as trazodone (marketed as Desyrel by Bristol-Myers Squibb), mirtazapine (marketed as Remeron by Organon Pharmaceuticals) and venlafaxine (marketed as Effexor by Pfizer) were associated with the highest risks for several negative outcomes.

Although further research is needed to confirm these findings, the authors state that the risks and benefits of different antidepressants should be carefully evaluated when they are prescribed to older patients.

3rd August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics